Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Zelnak · SciRah

Researcher profile · Semantic Scholar

A. Zelnak

Share profile

A. Zelnak — researcher profile on SciRah

h-index: 20
Works: 78
Citations: 3,733

Most-cited papers

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia, S. Hurvitz, S. Tolaney, D. Loirat +26 more
2021New England Journal of Medicine1,272 citations Open access
Semantic Scholar
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
N. Lin, V. Borges, C. Anders, R. Murthy +25 more
2020Journal of Clinical Oncology447 citations Open access
Semantic Scholar
Current approaches to the treatment of metastatic brain tumours
T. Owonikoko, J. Arbiser, A. Zelnak, H. Shu +10 more
2014Nature Reviews Clinical Oncology283 citations Open access
Semantic Scholar
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
N. Lin, R. Murthy, V. Abramson, C. Anders +23 more
2022JAMA Oncology184 citations Open access
Semantic Scholar
Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
A. Bardia, S. Tolaney, K. Punie, D. Loirat +23 more
2021Annals of Oncology183 citations Open access
Semantic Scholar
Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells*
Adam I. Marcus, U. Peters, Shala L. Thomas, S. Garrett +3 more
2005Journal of Biological Chemistry163 citations Open access
Semantic Scholar
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
K. Kalinsky, M. Accordino, C. Chiuzan, P. Mundi +19 more
2023Journal of Clinical Oncology156 citations
Semantic Scholar
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia, S. Tolaney, K. Punie, D. Loirat +24 more
146 citations
Semantic Scholar
Phase I/II trial of triplet therapy (exemestane, ribociclib, and everolimus) after progression on a CDK4/6 inhibitor in HR+/HER2– advanced breast cancer (TRINITI-1)
A. Bardia, S. Hurvitz, A. DeMichele, A. Clark +10 more
2021Clinical Cancer Research97 citations Open access
Semantic Scholar
Everolimus: side effect profile and management of toxicities in breast cancer
E. Paplomata, A. Zelnak, R. O'Regan
2013Breast Cancer Research and Treatment96 citations
Semantic Scholar
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
L. Goldstein, M. Mansutti, C. Lévy, Jenny C. Chang +49 more
2021Breast Cancer Research and Treatment77 citations Open access
Semantic Scholar
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
A. Schram, N. Colombo, E. Arrowsmith, V. Narayan +19 more
2022JAMA Oncology56 citations Open access
Semantic Scholar
The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation.
R. Prabhu, K. Godette, G. Carlson, A. Losken +5 more
2012International Journal of Radiation Oncology, Biology, Physics52 citations
Semantic Scholar
Optimizing Endocrine Therapy for Breast Cancer.
A. Zelnak, R. O'Regan
2015The Journal of the National Comprehensive Cancer Network47 citations Open access
Semantic Scholar
21‐Gene recurrence scores
M. Lund, M. Mosunjac, K. M. Davis, S. Gabram-Mendola +6 more
2012Cancer47 citations Open access
Semantic Scholar
Survivin Deregulation in β-Tubulin Mutant Ovarian Cancer Cells Underlies Their Compromised Mitotic Response to Taxol
Jun-Hao Zhou, A. O'Brate, A. Zelnak, P. Giannakakou
2004Cancer Research45 citations
Semantic Scholar
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
A. Bardia, S. Hurvitz, A. DeMichele, A. Clark +11 more
2019Journal of Clinical Oncology40 citations
Semantic Scholar
Overcoming Taxane and Anthracycline Resistance
A. Zelnak
2010The Breast Journal31 citations Open access
Semantic Scholar
The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
N. Jegadeesh, Sunjin Kim, R. Prabhu, G. Oprea +6 more
2014Annals of Surgical Oncology29 citations Open access
Semantic Scholar
Adjuvant hormonal therapy for early-stage breast cancer.
A. Zelnak, R. O'Regan
2008Cancer treatment and research21 citations
Semantic Scholar
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
V. Mueller, A. Wardley, E. Paplomata, E. Hamilton +27 more
2021European Journal of Cancer19 citations Open access
Semantic Scholar
Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer.
A. Zelnak, S. Murali, T. Styblo, G. Carlson +6 more
201319 citations
Semantic Scholar
Endocrine therapy for the treatment of postmenopausal women with breast cancer
S. Harichand-Herdt, A. Zelnak, R. O'Regan
2009Expert Review of Anticancer Therapy19 citations
Semantic Scholar
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab
Christine C. Davis, A. Zelnak, J. Eley, D. Goldstein +2 more
2016The Annals of Pharmacotherapy18 citations Open access
Semantic Scholar
High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
A. Zelnak, P. Nikolinakos, J. Srinivasiah, W. Jonas +5 more
2015Clinical Breast Cancer17 citations
Semantic Scholar
Improving on National Quality Indicators of Breast Cancer Care in a Large Public Hospital as a Means to Decrease Disparities for African American Women
M. Rizzo, H. Bumpers, J. Okoli, D. Senior-Crosby +6 more
2010Annals of Surgical Oncology16 citations
Semantic Scholar
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
D. Yee, A. Demichele, C. Isaacs, F. Symmans +75 more
201815 citations
Semantic Scholar
Clinical pharmacology and use of microtubule-targeting agents in cancer therapy.
A. Zelnak
2007Methods in Molecular Medicine15 citations
Semantic Scholar
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
N. Lin, R. Murthy, C. Anders, V. Borges +16 more
202012 citations
Semantic Scholar
Treatment adherence and outcome in women with inflammatory breast cancer
F. Andic, K. Godette, R. O'Regan, A. Zelnak +4 more
2011Cancer12 citations
Semantic Scholar
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Caitlin E Taylor, J. Meisel, A. Foreman, C. Russell +6 more
2023Breast Cancer Research and Treatment11 citations Open access
Semantic Scholar
Targeting Angiogenesis in Advanced Breast Cancer
A. Zelnak, R. O'Regan
2012BioDrugs11 citations
Semantic Scholar
Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
S. Hurvitz, S. Tolaney, K. Punie, D. Loirat +23 more
2021General Session Abstracts10 citations
Semantic Scholar
275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
V. Mueller, E. Paplomata, E. Hamilton, A. Zelnak +16 more
20208 citations Open access
Semantic Scholar
JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
D. Hyman, A. Zelnak, T. Bauer, S. Ulahannan +7 more
2019Journal of Clinical Oncology8 citations
Semantic Scholar
Genomic subtypes in choosing adjuvant therapy for breast cancer.
A. Zelnak, R. O'Regan
2013Oncology8 citations
Semantic Scholar
Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study
S. Moulder, M. Karuturi, D. Yardley, G. Wright +11 more
2018Clinical Trials6 citations
Semantic Scholar
Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
D. M. Marcus, J. Switchenko, R. Prabhu, R. O'Regan +4 more
2013Frontiers in Oncology6 citations Open access
Semantic Scholar
Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
E. Paplomata, A. Zelnak, C. Santa-Maria, Yuan Liu +6 more
2019Clinical Breast Cancer5 citations Open access
Semantic Scholar
Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.
A. Zelnak, T. Styblo, M. Rizzo, S. Gabram +5 more
2013Clinical Breast Cancer5 citations
Semantic Scholar
Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer
R. O'Regan, S. Gabram, T. Styblo, M. Rizzo +7 more
20124 citations
Semantic Scholar
Treatment Adherence and Outcome in Women with Inflammatory Breast Cancer: Does Race Matter?
F. Andic, K. Godette, R. O'Regan, A. Zelnak +4 more
20104 citations
Semantic Scholar
High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy.
A. Zelnak, B. Leyland-Jones, S. Gabram-Mendola, T. Styblo +6 more
20104 citations
Semantic Scholar
Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
S. Hurvitz, A. Clark, H. Rugo, A. Bardia +10 more
2022Cancer Research3 citations
Semantic Scholar
Targeted Therapy for Metastatic Breast Cancer
A. Zelnak, R. O'Regan
20103 citations
Semantic Scholar
Chemoprevention of breast cancer.
A. Zelnak, R. O'Regan
2004Current Problems in Cancer3 citations
Semantic Scholar
Abstract CT110: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer following progression on a CDK4/6 inhibitor: Safety, tolerability, and pharmacokinetic results from Phase 1 of TRINITI-1 study
S. Hurvitz, D. Yardley, A. Zelnak, A. DeMichele +8 more
20172 citations
Semantic Scholar
Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor
A. Bardia, S. Hurvitz, D. Yardley, A. Zelnak +6 more
20172 citations
Semantic Scholar
Special considerations in early-stage breast cancer patients and survivors.
A. Zelnak
2013Obstetrics and Gynecology Clinics of North America2 citations
Semantic Scholar
The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
C. Fasola, K. Godette, M. McDonald, R. O'Regan +3 more
20102 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. O'Regan×25
Invite
R. O'Regan — researcher profile on SciRah
S. Hurvitz×13
Invite
S. Hurvitz — researcher profile on SciRah
A. Bardia×10
Invite
A. Bardia — researcher profile on SciRah
M. Torres×8
Invite
M. Torres — researcher profile on SciRah

×8

Invite

M. Rizzo — researcher profile on SciRah

Invite

L. Carey — researcher profile on SciRah

Invite

S. Gabram — researcher profile on SciRah

Invite

H. Rugo — researcher profile on SciRah

E. Paplomata×6

Invite

E. Paplomata — researcher profile on SciRah

Invite

D. Yardley — researcher profile on SciRah

Invite

M. Oliveira — researcher profile on SciRah

Invite

E. Hamilton — researcher profile on SciRah